Member Info for GingetheWinge

That window is likely to be small. When HUA is granted Avacta will hear during office hours and an intraday RNS will appear out of nowhere. Hopefully very strong sales confirmed at the end of the month and then we can get back to discussing the company and its continued success and growth as the year closes.

I wouldn't agree that it's a high risk investment. There is risk, of course, but minimal.
Normally there needs to be high risk for a a chance of high reward. However, with AVACTA (particularly at this SP) there is low risk with very high potential gains. The company has unique and potentially astronomically valuable IP, an excellent staff base and several very promising developments in the pipeline which are fully funded for the next two years.
As has already been pointed out today the market has largely written off AffiDX already so it's a free spin of the wheel from here.

Sadly this was probably to be expected and doubtless Jupiter are very happy. It doesn't alter the fact that we are now very close to significant news and a substantial rerate. Weak hands and impatience will make you poorer.

More deliberate disruption using antivaccine nonsense.
There is absolutely ZERO evidence that anti-covid vaccination is damaging to fertility and long term health. There is overwhelming evidence that it has saved 100s of thousands of lives.

And ? Dentists are paid for every extraction. Mechanics are paid for every MOT.
Presumably disrupters and agents of foreign powers charged with spreading misinformation are also paid for piecework.
GPs have only administered a minority of total jabs in the UK anyway.

The only thing they are suppressing is severe disease and death. Oh, and misinformation.

This is to allow anyone holding existing stock to use it up. We have been told that we will no longer be supplied any further Innova tests and any future orders will be met with Orient Gene or Flowflex.

If/when HUA is awarded we'll be told immediately.

Well it's good news, in a strange way, if the true clinical performance is poor as it argues even more strongly for AffiDX.

It's a basic double nasal swab sampling rather than nose and throat. Data from FIND study :
CH (9 June 2021)
279 samples, nasal swab
Clinical sensitivities:
- Days < 7: 92.2%;
- Ct < 33: 98.3%;
- Ct < 25: 100%;
Clinical specificity: 99.5%

It may have taken longer than was hoped, but it is sounding as though this is all now falling in to place.

The government needs to be certain that daily orders for millions of tests are met and dispatched immediately. That means several manufacturers need to be involved and dealing with the Chinese for a short while longer.
It would be much worse not to meet the testing demand. Everything is moving in the right direction.

But better than Innova which is now history. Flowflex received self-testing CE at the end of May and I am guessing will now start to replace Orient Gene which is still professional use only. The stage is set for AffiDX.

Apparently advice is being given to users to continue with any existing Innova stock but future orders will be met with Orient Gene of Flowflex. Innova will no longer be supplied.

The NHS have now switched from sending out Orient Gene tests to ACON Flowflex.

I could talk about a longer term valuation based on a market cap of more than £5 billion. That might be called ramping at this stage, but that’s my hope and expectation. In the short to medium term >£5 per share is a perfectly reasonable expectation if everything happens as expected. Currently it looks as though we are on track - if a little behind schedule.

I didn’t say end of play.
SP is currently ridiculously low. Broker valuation is just sub £3. If the fabled 60 million a month is imminent then £6 a share could look cheap.

Depending on what’s in the RNS then 3-500% from here is entirely possible.

Feels like the long awaited confirmation of 30 million per month domestic and additional 30 million per month RoW manufacturing capacity is close now.

The point is it is a contract for only a fraction of what will be needed. Therefore, the question is who will be supplying the majority and when will that contract(s) be in the public domain ? It must be soon.